Nicolai Haugsted
Users of the weight loss medicine should be aware.
Weight-loss injections have already changed supermarket shopping, celebrity interviews and half the internet’s search history.
Now they may also affect your driving licence.
Millions of people taking GLP-1 drugs such as Ozempic, Wegovy and Mounjaro are being warned that certain side effects could land them with a fine of up to £1,000 if they continue driving without informing British authorities.
And yes — dizziness behind the wheel apparently counts as everybody’s problem now.
Weight-loss drugs trigger driving concerns
Experts in the UK are warning that some side effects linked to popular GLP-1 medications may fall under rules that require drivers to notify the DVLA, Britain’s driving authority.
Around 1.6 million people in Britain are believed to have used the drugs for weight loss over the past year alone.
Most people probably associate Ozempic and Mounjaro with shrinking waistlines and celebrities suddenly looking suspiciously “well-rested.” Less attention has gone toward what happens if the medication leaves drivers dizzy, exhausted or struggling to focus on traffic.
According to Ladbible via. Select Car Leasing, failing to report side effects that impair driving ability could result in serious penalties.
Side effects could affect driving
Pharmacists and motoring experts say symptoms linked to GLP-1 drugs may create safety risks on the road.
Reported side effects include dizziness, fatigue, nausea, vomiting, blurred vision, sweating, shakiness, confusion, stomach pain and impaired concentration.
Robert Bradshaw, superintendent pharmacist at Oxford Online Pharmacy, warned that some symptoms could directly impact reaction time and awareness behind the wheel.
“Dizziness may make it harder to focus on the road or could impair vision, making it unsafe to drive,” Bradshaw said.
“Persistent fatigue could also reduce alertness and slow down reaction time to hazards or traffic.”
He also warned that nausea can become a distraction while driving.
“Even nausea and stomach discomfort can quickly become distracting behind the wheel,” he added.
Combination with diabetes medication raises concerns
Health experts say particular caution is needed for people combining GLP-1 drugs with insulin or sulfonylurea medications such as gliclazide.
Together, those medications can increase the risk of hypoglycaemia — low blood sugar — which can trigger symptoms dangerous for drivers.
“Symptoms, including sweating, shakiness, confusion and blurred vision, can affect driving safety,” Bradshaw explained.
“If you notice any of these effects, it’s best to avoid driving until you feel well again.”
Most people won’t face problems
Officials stress that taking Ozempic or Mounjaro does not automatically mean someone should stop driving.
Graham Conway from Select Car Leasing said most users experience no major driving-related issues at all.
“Drivers may be surprised to learn that side effects from prescription medication, such as dizziness, can fall under the DVLA’s reporting requirements if those side effects affect someone’s ability to operate a vehicle safely,” Conway said.
“Failing to declare any medication-related issues that impair your driving could result in a £1,000 fine.”
Manufacturer Eli Lilly also states that Mounjaro has “no or negligible influence on the ability to drive,” though the company advises additional precautions when the drug is combined with insulin-related treatments.
Ebola-level panic? Not quite
Nobody is suggesting Ozempic users are suddenly public enemies every time they approach a roundabout.
British authorities simply require certain health conditions and impairments to be reported if they could affect safe driving — similar to rules already covering conditions such as sleep apnoea or severe diabetes.
Still, for a medication originally designed to lower blood sugar, Ozempic somehow continues finding new ways to dominate headlines.
